anthonyyazdaniml/CT-ADE-SOC huggingface dataset:
Intervention: Remdesivir
Trial phase: Phase 3
ATC code: J05AB16
SMILES: CCC(CC)COC(=O)[C@H](C)N[P@](=O)(OC[C@H]1O[C@@](C#N)(c2ccc3c(N)ncnn23)[C@H](O)[C@@H]1O)Oc1ccccc1
Sex: All
Age groups: Adult | Older Adult
Healthy volunteers: No
Participants at risk: 532
Group description: 200 mg of Remdesivir administered intravenously on Day 1, followed by a 100 mg once-daily maintenance dose of Remdesivir while hospitalized for up to a 10 days total course.
Eligibility criteria:
Inclusion Criteria:

Admitted to a hospital with symptoms suggestive of COVID-19 infection.
Subject (or legally authorized representative) provides informed consent prior to initiation of any study procedures.
Subject (or legally authorized representative) understands and agrees to comply with planned study procedures.
Male or non-pregnant female adult > / = 18 years of age at time of enrollment.

Has laboratory-confirmed SARS-CoV-2 infection as determined by polymerase chain reaction (PCR) or other commercial or public health assay in any specimen, as documented by either or the following:

PCR positive in sample collected < 72 hours prior to randomization; OR

Exclusion Criteria:

PCR positive in sample collected >/= 72 hours prior to randomization, documented inability to obtain a repeat sample (e.g. due to lack of testing supplies, limited testing capacity, results taking >24 hours, etc.) AND progressive disease suggestive of ongoing SARS-CoV-2 infection.

Illness of any duration, and at least one of the following:

Radiographic infiltrates by imaging (chest x-ray, CT scan, etc.), OR
SpO2 < / = 94% on room air, OR
Requiring supplemental oxygen, OR
Requiring mechanical ventilation.
Women of childbearing potential must agree to either abstinence or use at least one primary form of contraception not including hormonal contraception from the time of screening through Day 29.
Agrees to not participate in another clinical trial for the treatment of COVID-19 or SARS-CoV-2 through Day 29.

Exclusion Criteria:

Alanine Transaminase (ALT) or Aspartate Transaminase (AST) > 5 times the upper limit of normal.
Estimated glomerular filtration rate (eGFR) < 30 ml/min (including patients receiving hemodialysis or hemofiltration).
Pregnancy or breast feeding.
Anticipated discharge from the hospital or transfer to another hospital which is not a study site within 72 hours.
Allergy to any study medication.
Intervention: Buprenorphine Hydrochloride
Trial phase: Phase 4
SMILES: COC12CCC3(CC1C(C)(O)C(C)(C)C)C1Cc4ccc(O)c5c4C3(CCN1CC1CC1)C2O5.Cl
Sex: All
Age groups: Adult | Older Adult
Healthy volunteers: No
Participants at risk: 14
Group description: Subjects will be given BUP 32mg in 2 doses, and observed for at least 90 minutes after the 2nd dose. The whole process will take a total of about 3-4 hours including the consenting process. Subjects will be asked questions and be examined repeatedly. Subjects will have 4 in-person visits and a phone call in addition to review of medical records.

Buprenorphine Naloxone: Participants will receive the BUP SL 32mg in divided doses rather than all at once. If after the initial 8mg dose a participant experiences over-sedation or another adverse event that would preclude further dosing, such as an allergic reaction, the subsequent dose will not be administered and the patient will be withdrawn from the study. The participant will be reassessed for other possible etiologies for these symptoms.
Eligibility criteria:
Inclusion Criteria:

Is able to speak English sufficiently to understand the study procedures and provide written informed consent to participate in the study.
Meets DSM-5 criteria for moderate to severe OUD
Has a positive urine screen for opioids and a negative urine screen for methadone
Must be experiencing opioid withdrawal with a COWS score ≥8
Is willing and able to participate in the study and follow study procedures
Is able to provide adequate and reliable locator information for follow-up
Has reliable access to a phone

Exclusion Criteria:

Is currently engaged in medication treatment for OUD with methadone, BUP, or naltrexone
Has a urine toxicology test that is positive for methadone or buprenorphine
Currently requires prescribed opioids for treatment of an ongoing pain condition
Has a known allergy to BUP
Is pregnant as determined by urine hCG testing at the index ED visit
Is breastfeeding as determined by self-report
Has medical, psychiatric, or concurrent substance use conditions or severe cognitive impairment which might prelude safe participation
Is a prisoner or in police custody at the time of the index ED visit
Has previously enrolled in the current study
Intervention: Bupivacaine
Trial phase: Phase 4
ATC code: N01BB01 | N01BB10 | N01BB51 | N01BB59
SMILES: CCCCN1CCCCC1C(=O)Nc1c(C)cccc1C
Sex: Female
Age groups: Adult | Older Adult
Healthy volunteers: No
Participants at risk: 21
Group description: Group 1 will receive an injection of 166mg of Depobupivacaine diluted in 60 ml.

Depobupivacaine: surgeons receive schematic for injection of Depobupivacaine. Subjects receive an injection of 166mg depobupivacaine. Injection on either side of the suture line, injected directly into the fascia.
Eligibility criteria:
Inclusion Criteria:

Non pregnant women
age 18 years or older
scheduled to have unilateral DIEP flap breast reconstruction.
Must have ASA physical status classification of 1,2, or 3

Exclusion Criteria:

concurrent or recent medical condition that could interfere with study participation
history of any of the following:
hepatitis
alcohol/substance abuse
uncontrolled psychiatric disorders
known allergy/ contraindication to any of the following:
amide-type local anesthetics
opioids
propofol
Body weight of less than 50 kg
have participated in another study involving an investigational medication with in the past 30 days
taking analgesics, antidepressants, or glucocorticoids within the 3 days before surgery
Intervention: Bupivacaine
Trial phase: Phase 4
ATC code: N01BB01 | N01BB10 | N01BB51 | N01BB59
SMILES: CCCCN1CCCCC1C(=O)Nc1c(C)cccc1C
Sex: Female
Age groups: Adult | Older Adult
Healthy volunteers: No
Participants at risk: 21
Group description: Group 3: The 0.25% bupivacaine patients will receive 2mg/kg of 0.25% bupivacaine.

0.25% Bupivacaine: group 3: given 0.25% bupivacaine without epinephrine between internal oblique and transverse abdominal muscle.
Eligibility criteria:
Inclusion Criteria:

Non pregnant women
age 18 years or older
scheduled to have unilateral DIEP flap breast reconstruction.
Must have ASA physical status classification of 1,2, or 3

Exclusion Criteria:

concurrent or recent medical condition that could interfere with study participation
history of any of the following:
hepatitis
alcohol/substance abuse
uncontrolled psychiatric disorders
known allergy/ contraindication to any of the following:
amide-type local anesthetics
opioids
propofol
Body weight of less than 50 kg
have participated in another study involving an investigational medication with in the past 30 days
taking analgesics, antidepressants, or glucocorticoids within the 3 days before surgery
Intervention: Bimatoprost
Trial phase: Phase 3
ATC code: S01EE03
SMILES: CCNC(=O)CCC/C=C\C[C@@H]1[C@@H](/C=C/[C@@H](O)CCc2ccccc2)[C@H](O)C[C@@H]1O
Sex: All
Age groups: Adult | Older Adult
Healthy volunteers: No
Participants at risk: 6
Group description: Participants will receive topical LUMIGAN 0.01% in the study eye once daily starting evening Dose on Day 1 and standard of care treatment in the fellow eye for the duration of the study.

LUMIGAN: Treatment with LUMIGAN 0.01% begins on Day 1. The drop will be instilled once daily in the evening to the study eye throughout the duration of the study.
Eligibility criteria:
Inclusion Criteria:

Diagnosis of either OAG or OHT study eye, requiring IOP-lowering treatment
Participant is currently a nonsmoker and has not smoked any nicotine-containing products within the previous 6 months

Exclusion Criteria:

Current or anticipated enrollment in another investigational drug or device study
Females who are pregnant, nursing, or planning a pregnancy during the study
Intervention: Calcitriol
Trial phase: Phase 1
ATC code: A11CC04 | D05AX03
SMILES: [H][C@@]12CC[C@]([H])([C@H](C)CCCC(C)(C)O)[C@@]1(C)CCC/C2=C\C=C1\C[C@@H](O)C[C@H](O)C1=C
Sex: All
Age groups: Adult
Healthy volunteers: Accepts Healthy Volunteers
Participants at risk: 4
Group description: Calcitriol (1,25(OH)2D3) 0.25mcg capsule daily for eight weeks.

Calcitriol capsules: 0.25micrograms, taken daily for eight weeks, orally
Eligibility criteria:
Inclusion Criteria:

Body mass index (BMI) of >24kg/m2
Fasting serum glucose <126 mg/dL

Exclusion Criteria:

BMI</=24 kg/m2
Fasting serum glucose >/=126 mg/dL
Patient is taking Calcium or Vitamin D supplements and is unwilling to stop for 8 weeks
Serum Calcium >10.2 mg/dL
Serum inorganic phosphorous >4.5mg/dL
Pregnancy or breastfeeding
Diagnosis of Diabetes Mellitus
Diagnosis of Rheumatoid Arthritis
Diagnosis of Chronic Obstructive Pulmonary Disease (COPD)
Renal in sufficiency/failure ( serum creatinine >1.5 mg/dL men, > 1.3 mg/dL women)
Chronic active liver disease (bilirubin >1.2 mg/dL, AST>144IU/L, or ALT >165 IU/L)
History of chronic hepatitis
Active coronary artery disease ( unstable angina, myocardial infarction, stroke and revascularization of coronary, peripheral or carotid artery within the last 3 months)
Oral warfarin group medications or history of blood clotting disorders
Platelet count <100,000 per uL within the last 7 days
Alcohol consumption greater than 2 glasses/day or other substance abuse
Untreated or uncontrolled thyroid disorders (outside a TSH range of 0.5 to 10mIU/L)
Debilitating chronic disease (at the discretion of the investigators)
The presence of infections, highly communicable diseases ( AIDS, active tuberculosis, venereal disease, hepatitis)
Any malignancy
Intervention: Levothyroxine
Trial phase: Phase 4
ATC code: C10AX01 | H03AA01 | H03AA51
SMILES: N[C@@H](Cc1cc(I)c(Oc2cc(I)c(O)c(I)c2)c(I)c1)C(=O)O
Sex: All
Age groups: Adult | Older Adult
Healthy volunteers: No
Participants at risk: 21
Group description: Continue the current dose of levothyroxine. The brand of levothyroxine to be used in this study will be Synthroid tablets of 25 mcg, 50 mcg, and 75 mcg (AbbVie Inc).

Levothyroxine: Participants will be instructed to start the study medication the day after randomization. The study medication will be taken orally once a day.
Eligibility criteria:
Inclusion Criteria:

Veterans
diagnosis of SCH

Exclusion Criteria:

thyroid-stimulating hormone (TSH) > 10 milli-international units per liter (mlU/L) (at any point)
Levothyroxine (LT4) dose more than 75 mcg daily
use of antithyroid medications, amiodarone, tyrosine kinase inhibitors or lithium
history of thyroidectomy or radioactive iodine therapy
LT4 suppressive therapy for thyroid cancer, goiter, or inflammation
pregnancy or plans for pregnancy in the next 6 months
an unstable medical condition that would jeopardize safety or interfere with study participation
severe hypothyroidism-related symptoms
strong family history of hypothyroidism
severe dyslipidemia
hospitalization for major illness within the previous 4 weeks
acute coronary artery syndrome, acute myocarditis, or pancarditis with the previous 12 months
grade IV New York Heart Association heart failure
receiving services from hospice
lack of decision-making capacity
terminal medical condition for which life expectancy would be less than 6 months
not willing to stop LT4
self-reported non-adherence to LT4 therapy
abnormal TSH at time of screening for participation (assessed during Baseline Visit)
Intervention: Gabapentin
Trial phase: Early Phase 1
ATC code: N02BF01 | N03AX12
SMILES: NCC1(CC(=O)O)CCCCC1
Sex: Female
Age groups: Adult | Older Adult
Healthy volunteers: Accepts Healthy Volunteers
Participants at risk: 219
Group description: Gabapentin 600 mg given 1-2 hours prior to surgical abortion

Gabapentin: Preoperative treatment with Gabapentin
Eligibility criteria:
Inclusion Criteria:

Women seeking surgical abortion between 5 and 23 6/7 weeks of ultrasound age.
English or Spanish speaking
eligible for office-based surgical pregnancy termination

Exclusion Criteria:

present use of gabapentin or pregabalin,
renal disease
sensitivity or allergy to gabapentin
Missed abortion
Intervention: Dronabinol
Trial phase: Early Phase 1
ATC code: A04AD10
SMILES: [H][C@@]12C=C(C)CC[C@@]1([H])C(C)(C)Oc1cc(CCCCC)cc(O)c12
Sex: All
Age groups: Adult
Healthy volunteers: Accepts Healthy Volunteers
Participants at risk: 24
Group description: Dronabinol: THC (Marinol® [dronabinol]; Solvay Pharmaceuticals) will be orally administered in doses of 7.5 mg and 15 mg, in opaque capsules with dextrose filler. Placebo capsules contain only dextrose. These doses of THC are known to produce performance impairments as well as subjective intoxication with little to no adverse reactions in experienced occasional, but non-daily cannabis users.
Eligibility criteria:
Inclusion Criteria:

18-20 years old OR 30-40 years old
Body Mass Index 19-26
High school education, fluent in English
Occasional cannabis users ( 0 times in past 30 days AND used cannabis no more than 20 times in lifetime)

Exclusion Criteria:

History of daily cannabis use
Past or present severe substance use disorder
Current or past diagnosis with drug treatment for psychosis/bipolar/schizophrenia
Cardiovascular illness, high blood pressure, abnormal electrocardiogram
Current medications
Pregnant or planning to become pregnant
Intervention: ISOSORBIDE DINITRATE
Trial phase: Phase 2
ATC code: C01DA08 | C01DA58 | C05AE02
SMILES: [H][C@]12OC[C@@H](O[N+](=O)[O-])[C@@]1([H])OC[C@@H]2O[N+](=O)[O-]
Sex: All
Age groups: Child | Adult | Older Adult
Healthy volunteers: No
Participants at risk: 20
Group description: Isosorbide Dinitrate therapy was initiated at a low dose (e.g. 5 mg three times daily in patients above 50 kg) and increased incrementally over 2 weeks to a goal of 30 mg three times a day. The medication was then continued for approximately 4 weeks once the target dose was achieved for a total of 6 weeks.
Eligibility criteria:
Inclusion Criteria:

Underlying Fontan physiology
On a stable medication regimen for the past 3 months
Nine years of age or older

Exclusion Criteria:

Pregnant or nursing
Prior hospitalization for heart failure in past year
Presence of uncontrolled arrhythmias within the past 6 months
Non-cardiac conditions which significantly limited exercise
Moderate or severe ventricular dysfunction by echocardiogram or cardiac MRI
Currently treated with a phosphodiesterase-5 inhibitor or organic nitrates
Concurrent enrollment in other investigational drug trial
End stage Liver Disease (ESLD)
Intervention: Propranolol
Trial phase: Phase 3
ATC code: C07AA05 | C07BA05 | C07FX01
SMILES: CC(C)NCC(O)COc1cccc2ccccc12
Sex: Female
Age groups: Child | Adult | Older Adult
Healthy volunteers: Accepts Healthy Volunteers
Participants at risk: 84
Group description: IV Propranolol - 2mg; one possible repeat dose ≥2 hours later

Propranolol Hydrochloride: 2mg/mL vials
Eligibility criteria:
Inclusion Criteria:

English-speaking

>= 36 weeks gestation

Singleton pregnancy

Vertex presentation

No contraindication to a vaginal delivery

Meets at least one study criteria for prolonged labor:

cervical dilation <6 cm after ≥8 hours with ruptured membranes and receiving oxytocin OR
cervical dilation >=6 cm and <1 cm dilation change over ≥2 hours with ruptured membranes and receiving oxytocin

Exclusion Criteria:

Severe preeclampsia: as patients will be receiving magnesium and possibly labetalol for hypertension control

Receiving other beta blocker

Maternal heart rate < 70 beats per minute, systolic blood pressure <90 mmHg, or diastolic blood pressure <50 mmHg on two sets of vital signs in the 1 hour prior to study drug administration: given that bradycardia and hypotension are possible side effects of propranolol

History of any form of asthma: as this is a contraindication to beta blocker use

Diabetes requiring insulin in labor: given the potential risk of neonatal hypoglycemia in the neonate

Any cardiac condition for which β blockade is contraindicated (cardiogenic shock, sinus bradycardia, and greater than first degree heart block)

Known hypersensitivity to propranolol

Intrauterine fetal demise since different labor protocols are used in these women

Major fetal congenital anomaly since rate of cesarean may be inherently different in these women, unrelated to labor
Intervention: BENZOYL PEROXIDE
Trial phase: Phase 4
ATC code: D10AE01 | D10AE51
SMILES: O=C(OOC(=O)c1ccccc1)c1ccccc1
Sex: Male
Age groups: Adult | Older Adult
Healthy volunteers: Accepts Healthy Volunteers
Participants at risk: 20
Group description: 5% Topical Benzoyl Peroxide Gel: Gel treatment used to treat acne
Eligibility criteria:
Inclusion Criteria:

Healthy male
18 years or older

Exclusion Criteria:

Allergy to benzoyl peroxide or chlorhexidine
<18 years of age
Previous history of shoulder infections
Antibiotics taken within one month of research visit
Immunocompromised state
Active cancer
Diabetic
Skin lesions or abrasions over the deltopectoral interval
Topical corticosteroid treatment to either shoulder or or systemic corticosteroid treatment within 2 weeks of research visit
Topical benzoyl peroxide treatment to either shoulder within 2 weeks of research visit
Blue light therapy treatment to either shoulder within 2 weeks of research visit
Prior incision over the deltopectoral interval of either shoulder
Contraindication to blue light treatment
Intervention: Losartan
Trial phase: Phase 2
ATC code: C09CA01 | C09DA01 | C09DB06
SMILES: CCCCc1nc(Cl)c(CO)n1Cc1ccc(-c2ccccc2-c2nn[nH]n2)cc1
Sex: All
Age groups: Adult | Older Adult
Healthy volunteers: No
Participants at risk: 58
Group description: Participants in this arm will receive the study drug, Losartan.

Losartan: Losartan; 25 mg daily; oral administration
Eligibility criteria:
Inclusion Criteria:

Positive laboratory test for COVID-19 based on local laboratory standard
Age greater than or equal to 18 years of age
One of the following: Upper respiratory symptoms (cough, rhinorrhea) or fever (>101.5) or loss of taste / smell

Exclusion Criteria:

Randomization > 72 hours of meeting inclusion criteria
Randomization > 7 days of symptom onset
Currently taking an angiotensin converting enzyme inhibitor (ACEi) or Angiotensin receptor blocker (ARB)
Prior reaction or intolerance to an ARB or ACE inhibitor, including but not limited to angioedema
Pregnant or breastfeeding women
Females able to have children not currently taking a protocol allowed version of contraception: intrauterine device, Depo-formulation of hormonal contraception (e.g. medroxyprogesterone acetate/Depo-Provera), subcutaneous contraceptive (e.g. Nexplanon), daily oral contraceptives with verbalized commitment to taking daily throughout the study, condom use or abstinence during the study. All participants of child bearing potential enrolled in this fashion will be informed of the teratogenic risks.

Patient reported history or electronic medical record history of kidney disease, defined as:

Any history of dialysis
History of chronic kidney disease stage IV
Estimated Glomerular Filtration Rate (eGFR) of < 30ml/min/1.73 m2 (must be have been measured within 1 month of enrollment)
Other kidney disease that in the opinion of the investigator, would affect losartan clearance
Patient reported dehydration and significantly decreased urine output in the past 72 hours
Most recent systolic blood pressure prior to enrollment <110 mmHg

Patient reported history or electronic medical record history of severe liver disease, defined as:

Cirrhosis
History of hepatitis B or C
Other liver disease that in the opinion of the investigator, would affect losartan clearance
Documented AST or ALT > 3 times the upper limit of normal within 3 months of randomization (if available in electronic medical record)
Potassium >5.0 mmol/L (must have been measured within 1 month) of enrollment
Concurrent treatment with aliskiren
Inability to obtain informed consent
Enrollment in another blinded randomized clinical trial for COVID
Intervention: Losartan
Trial phase: Phase 2
ATC code: C09CA01 | C09DA01 | C09DB06
SMILES: CCCCc1nc(Cl)c(CO)n1Cc1ccc(-c2ccccc2-c2nn[nH]n2)cc1
Sex: All
Age groups: Adult | Older Adult
Healthy volunteers: No
Participants at risk: 101
Group description: Participants in this arm will receive the study drug, Losartan.

Losartan: Losartan; 50 mg daily; oral administration
Eligibility criteria:
Inclusion Criteria:

Presumptive positive laboratory test for Covid-19 based on local laboratory standard
Age greater than or equal to 18 years of age
Admission to the hospital with a respiratory SOFA >=1 and increased oxygen requirement compared to baseline among those on home O2
Randomization within 48 hours of presentation of hospital admission or within 48 hours of a positive test result, whichever is later

Exclusion Criteria:

Randomization > 48 hours of admission order or positive test result, whichever is later
Currently taking an angiotensin converting enzyme inhibitor (ACEi) or Angiotensin receptor blocker (ARB)
Prior reaction or intolerance to an ARB or ACE inhibitor, including but not limited to angioedema
Pregnant or breastfeeding
Lack of negative urine or serum pregnancy test
Not currently taking a protocol allowed version of contraception: intrauterine device, Depo-formulation of hormonal contraception (e.g. medroxyprogesterone acetate / Depo-Provera), subcutaneous contraceptive (e.g. Nexplanon), daily oral contraceptives with verbalized commitment to taking daily throughout the study period; use of condoms or agree to abstain from sexual intercourse during the study. All women of child bearing age enrolled in this fashion will be informed of the teratogenic risks. If enrolled under LAR, they will be informed of the risks after regaining capacity.

Patient reported history or electronic medical record history of kidney disease, defined as:

Any history of dialysis
History of chronic kidney disease stage IV
Estimated Glomerular Filtration Rate (eGFR) of < 30ml/min/1.73 m2 at the time of randomization
Severe dehydration at the time of enrollment in the opinion of the investigator or bedside clinician
Most recent mean arterial blood pressure prior to enrollment <65 mmHg

Patient reported history or electronic medical record history of severe liver disease, defined as:

Cirrhosis
History of hepatitis B or C
Documented AST or ALT > 3 times the upper limit of normal measured within 24 hours prior to randomization
Potassium >5.0 within 24 hours prior to randomization unless a repeat value was <=5.0
Treatment with aliskiren
Inability to obtain informed consent from participant or legally authorized representative
Enrollment in another blinded randomized clinical trial for COVID
Intervention: Azithromycin
Trial phase: Phase 4
ATC code: J01FA10 | J01RA07 | J01RA16 | S01AA26
SMILES: CCC1OC(=O)C(C)C(OC2CC(C)(OC)C(O)C(C)O2)C(C)C(OC2OC(C)CC(N(C)C)C2O)C(C)(O)CC(C)CN(C)C(C)C(O)C1(C)O
Sex: All
Age groups: Child
Healthy volunteers: Accepts Healthy Volunteers
Participants at risk: 220
Group description: A single dose of azithromycin will be administered to children between the ages of 8 days and 59 months old.

Azithromycin: Zithromax® for oral suspension is supplied in bottles containing azithromycin dehydrate powder equivalent to 1200mg per bottle and the following inactive ingredients: sucrose; tribasic anhydrous sodium phosphate; hydroxypropyl cellulose; xanthan gum; FD&C Red #40; and flavoring including spray dried artificial cherry, crème de vanilla, and banana. After constitution, a 5mL suspension contains 200mg of azithromycin.
Eligibility criteria:
Inclusion Criteria:

Between 8 days and 59 months old
Primary residence within catchment area of study site
Available for full 6 month study
No known allergy to macrolides/azalides
Appropriate written informed consent from at least one parent or guardian
Able to feed orally

Exclusion Criteria:

<8 days old or >59 months
Primary residence outside catchment area of study site
Not available for full 6 month study
Known allergy to macrolides/azalides
No written informed consent from at least one parent or guardian
Unable to feed orally